Selective serotonin reuptake inhibitors and torsade de pointes: New concepts and new directions derived from a systematic review of case reports

Therapeutic Advances in Drug Safety

Volumn 4, Issue 5, 2013, Pages 189-198

  Kogut, Christopher ^a   Crouse, Ericka Breden ^b   Vieweg, W Victor R ^b   Hasnain, Mehrul ^c   Baranchuk, Adrian ^d   Digby, Geneviève C ^d   Koneru, Jayanthi N ^a   Fernandez, Antony ^a   Deshmukh, Anand ^e   Hancox, Jules C ^f   Pandurangi, Ananda K ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

^e CREIGHTON UNIVERSITY CARDIAC CENTER   (United States)

^f UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

antidepressant drugs; QTc interval prolongation; SSRIs; torsade de pointes

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; PAROXETINE; POTASSIUM CHANNEL HERG; SERTRALINE; VENLAFAXINE;

ARTICLE; CARDIOVASCULAR RISK; DEPOLARIZATION; DRUG OVERDOSE; DRUG SAFETY; ELECTROCARDIOGRAM; ELECTRONIC MEDICAL RECORD; FAINTNESS; HEART ARRHYTHMIA; HEART DISEASE; HEART ELECTROPHYSIOLOGY; HUMAN; HYPOKALEMIA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; REPOLARIZATION; SEX DIFFERENCE; SYSTEMATIC REVIEW; TACHYCARDIA; TORSADE DES POINTES; WEAKNESS;

EID: 84890231486     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098613492366     Document Type: Article

References (73)

1. Appleby M. Mbewu A. Clarke B. (1995) Fluoxetine and ventricular torsade – is there a link? Int J Cardiol 49: 178–180.
2. Astrom-Lilja C. Odeberg J. Ekman E. Hagg S. (2008) Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemioland Drug Saf 17: 587–592.
3. Azaz-Livshits T. Danenberg H. (1997) Tachycardia, orthostatic hypotension and profound weakness due to concomitant use of fluoxetine and nifedipine. Pharmacopsychiatry 30: 274–275.
4. Bednar M. Harrigan E. Anziano R. Camm A. Ruskin J. (2001) The QT interval. Prog Cardiovasc Dis 43(Suppl.): 1–45.
5. Bednar M. Harrigan E. Ruskin J. (2002) Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am J Cardiol 89: 1316–1319.
6. Blaschke D. Parwani A. Huemer M. Rolf S. Boldt L. Dietz R. (2007) Torsade de pointes during combined treatment with risperidone and citalopram. Pharmacopsychiatry 40: 294–295.
7. Bazian (2012) Antidepressant citalopram heart safety warning, PubMed Health. Available from: http://www.ncbi.nlm.nih.gov/pubmedhealth/behindtheheadlines/news/2012-07-02-antidepressant-citalopram-heart-safety-warning/ (accessed 15 May 2013).
8. Brzozowska A. Werner B. (2009) Observation of QTc Prolongation in an Adolescent Girl During Fluvoxamine Pharmacotherapy. J Child Adolesc Psychopharmacol 19: 591–592.
9. Buchanan Keller K. Lemberg L. (2008) ‘Torsade–. Am J Crit Care 17: 77–81.
10. Camm A. Malik M. Yap Y. (2004) Acquired Long QT Syndrome. London: Blackwell Futura.
11. Castro V. Clements C. Murphy S. Gainer V. Fava M. Weilburg J. (2013) QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 346: f288.
12. Darpö B. (2001) Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J 3(Suppl. K): K70–K80.
13. De Gregorio C. Morabito G. Cerrito M. Dattilo G. Oreto G. (2011) Citalopram-induced long QT syndrome and torsade de pointes: role for concomitant therapy and disease. Int J Cardiol 148: 226–228.
14. De La Torre B. Dreher J. Malevany I. Bagli M. Kolbinger M. Omran H. (2001) Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther Drug Monitoring 23: 435–440.
15. Deamer R. Wilson D. Clark D. Prichard J. (2001) Torsades de pointes associated with high dose levomethadyl acetate (Orlaam®). J Addict Dis 20: 7–15.
16. Deshmukh A. Ulveling K. Alla V. Abuissa H. Airey K. (2012) Prolonged QTc interval and torsades de pointes induced by citalopram. Texas Heart Inst J 39: 68–70.
17. Dessertenne F. (1966) Tachycardie ventriculaire a deux foyers opposes variables. Arch Mal Coeur Vaiss 59: 263–272.
18. Digby G. Machaalany J. Malik P. Methot M. Simpson C. Redfearn D. (2010) Multifactorial QT interval prolongation. Cardiol J 17: 184–188.
19. Doyle M. Rosenthal L. (2013) Psychotropic medications, associated QTc prolongationand sudden cardiac death: a review for clinicians. Psychiatric Annals 43: 58–65.
20. European Medicines Agency (EMA) (2011) Pharmacovigilance Working Party (PhVWP), monthly report, October 2011 plenary meeting. London: EMA.
21. Fayssoil A. Issi J. Guerbaa M. Raynaud J. Heroguelle V. (2011) Torsade de pointes induced by citalopram and amiodarone. Ann Cardiol Angéiol 60: 165–168.
22. Fisch C. (1985) Effect of fluoxetine on the electrocardiogram. J Clin Psychiatry 46: 42–44.
23. Food and Drug Administration (FDA) (2011) FDA Drug Safety Communication: abnormal heart rhythms associated with high doses of celexa (citalopram hydrobromide), 24 August 2011. Washington DC: FDA. Available from: http://www.FDA.Gov/Drugs/Drugsafety/Ucm269086.Htm (accessed 15 May 2013).
24. Food and Drug Administration (FDA) (2012) FDA Drug Safety Communication: revised recommendations for celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses, 28 March 2012. Washington DC: FDA. Available from: http://www.fda.gov/drugs/drugsafety/ucm297391.htm (accessed 15 May 2013).
25. Forest Laboratories (2011) Celexa (citalopram hydrobromide) causes dose dependent QT prolongation. New York: Forest Laboratories, Inc. http://www.frx.com/pdf/DearDrCelexa%20HCP%20Letter%2008_12_2011.pdf (accessed 15 May 2013).
26. Fossa A. Gorczyca W. Wisialowski T. Yasgar A. Wang E. Crimin K. (2007) Electrical alternans and hemodynamics in the anesthetized guinea pig can discriminate the cardiac safety of antidepressants. J Pharmacol Toxicol Methods 55: 78–85.
27. Franz M. (2008) Bazett, Fridericia, or Malik? Heart Rhythm 5: 1432–1433.
28. Gintant G. (2008) Preclinical torsades-de-pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk. Pharmacol Ther 119: 199–209.
29. Gintant G. Limberis J. McDermott J. Wegner C. Cox B. (2001) The canine purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Cardiovascul Pharmacol 37: 607–618.
30. Goldenberg I. Moss A. Zareba W. (2006) QT interval: how to measure it and what is ‘normal–. J Cardiovascul Electrophysiol 17: 333–336.
31. Grundemar L. Wohlfart B. Lagerstedt C. Bengtsson F. Eklundh G. (1997) Symptoms and signs of severe citalopram overdose. Lancet 349: 1602.
32. Hancox J. McPate M. El Harchi A. Zhang Y. (2008) The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol Ther 119: 118–132.
33. Hancox J. Mitcheson J. (2006) Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology. Br J Pharmacol 149: 457–459.
34. Hayes B. Klein-Schwartz W. Clark R. Muller A. Miloradovich J. (2010) Comparison of toxicity of acute overdoses with citalopram and escitalopram. J Emerg Med 39: 44–48.
35. Henry M. Schmidt M. Hennen J. Villafuerte R. Butman M. Tran P. (2005) A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: a 19-F MRS study. Neuropsychopharmacology 30: 1576–1583.
36. Isbister G. Friberg L. Stokes B. Buckley N. Lee C. Gunja N. (2007) Activated charcoal decreases the risk of QT prolongation after citalopram overdose. Ann Emerg Med 50: 593–600.
37. Jimmink A. Caminada K. Hunfeld N. Touw D. (2008) Clinical toxicology of citalopram after acute intoxication with the sole drug or in combination with other drugs: overview of 26 cases. Ther Drug Monitoring 30: 365–371.
38. Kanjanauthai S. Kanluen T. Chareonthaitawee P. (2008) Citalopram induced torsade de pointes, a rare life threatening side effect. Int J Cardiol 131: e33–e34.
39. Kannankeril P. (2008) Understanding drug-induced torsades de pointes: a genetic stance. Expert Opin Drug Saf 7: 231–239.
40. Khalifa M. Daleau P. Turgeon J. (1999) Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther 291: 280–284.
41. Lauer M. (2012) From hot hands to declining effects: the risks of small numbers. J Am Coll Cardiol 60: 72–74.
42. Letsas K. Korantzopoulos P. Pappas L. Evangelou D. Efremidis M. Kardaras F. (2006) QT interval prolongation associated with venlafaxine administration. Int J Cardiol 109: 116–117.
43. Manet P. Hilpert F. Fouet P. Toledano D. (1993) Ventricular arrhythmia during fluvoxamine poisoning. Therapie 48: 62–63.
44. McAnally L. Threlkeld K. Dreyling C. (1992) Case report of a syncopal episode associated with fluoxetine. Ann Pharmacother 26: 1090–1091.
45. Michalets E. Smith L. Van Tassel E. (1998) Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction. Ann Pharmacother 32: 761–765.
46. Milnes J. Crociani O. Arcangeli A. Hancox J. Witchel H. (2003) Blockade of hERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol 139: 887–898.
47. Ohtani H. Odagiri Y. Sato H. Sawada Y. Iga T. (2001) A comparative pharmacodynamic study of the arrhythmogenicity of antidepressants, fluvoxamine and imipramine, in guinea Pigs. Biol Pharmaceut Bull 24: 550–554.
48. Orsulak P. Kenney J. Debus J. Crowley G. Wittman P. (1988) Determination of the antidepressant fluoxetine and its metabolite norfluoxetine in serum by reversed-phase HPLC with ultraviolet detection. Clin Chem 34: 1875–1878.
49. Pacher P. Magyar J. Szigligeti P. Banyasz T. Pankucsi C. Korom Z. (2000) Electrophysiological effects of fluoxetine in mammalian cardiac tissues. Naunyn-Schmiedeberg–s Arch Pharmacol 361: 67–73.
50. Patanè S. Marte F. Di Bella G. (2009) QT interval prolongation and torsade de pointes. Int J Cardiol 131: e51–e53.
51. Personne M. Persson H. Sjoberg E. (1997a) Citalopram toxicity. Lancet 350: 518–519.
52. Personne M. Sjoberg G. Persson H. (1997b) Citalopram overdose – review of cases treated in Swedish hospitals. J Toxicol Clin Toxicol 35: 237–240.
53. Poluzzi E. Raschi E. Moretti U. De Ponti F. (2009) Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf 18: 512–518.
54. Psychiatric News (2000) Lilly halts clinical trials of new antidepressant, Psychiatric News, 1 December 2000. Available from: http://psychnews.org/pnews/00-12-01/lilly.html (accessed 15 May 2013).
55. Rajamani S. Eckhardt L. Valdivia C. Klemens C. Gillman B. Anderson C. (2006) Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 149: 481–489.
56. Raschi E. Ceccarini L. De Ponti F. Recanatini M. (2009) hERG-related drug toxicity and models for predicting hERG liability and QT pProlongation. Expert Opin Drug Metab Toxicol 5: 1005–1021.
57. Rasmussen S. Overo K. Tanghoj P. (1999) Cardiac safety of citalopram: prospective trials and retrospective analyses. J Clin Psychopharmacol 19: 407–415.
58. Sanguinetti M. Tristani-Firouzi M. (2006) hERG potassium channels and cardiac arrhythmia. Nature 440: 463–469.
59. Taleb N. (2010) The Black Swan, 2nd ed. New York: Random House.
60. Tarabar A. Hoffman R. Nelson L. (2008) Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest. J Med Toxicol 4: 101–105.
61. Thomas D. Gut B. Wendt-Nordahl G. Kiehn J. (2002) The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (hERG) potassium channels. J Pharmacol Exp Ther 300: 543–548.
62. Upward J. Edwards J. Goldie A. Waller D. (1988) Comparative Effects of Fluoxetine and Amitriptyline on Cardiac Function. Br J Clin Pharmacol 26: 399–402.
63. Varriale P. (2001) Fluoxetine (Prozac) as a cause of QT prolongation. Arch Intern Med 161: 612.
64. Vieweg W. Wood M. Fernandez A. Beatty-Brooks M. Hasnain M. Pandurangi A. (2009) Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 26: 997–1012.
65. Waring W. Graham A. Gray J. Wilson A. Howell C. Bateman D. (2010) Evaluation of a QT nomogram for risk assessment after antidepressant overdose. Br J Clin Pharmacol 70: 881–885.
66. Weeke P. Jensen A. Folke F. Gislason G. Olesen J. Andersson C. (2012) Antidepressant use and risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Clin Pharmacol Ther 92: 72–79.
67. Wenzel-Seifert K. Wittmann M. Haen E. (2011) QTc Prolongation by psychotropic drugs and the risk of torsade de pointes. Dtsch Arztebl Int 108: 687–693.
68. Wilting I. Smals O. Holwerda N. Meyboom R. De Bruin M. Egberts T. (2006) QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine. Am J Psychiatry 163: 325.
69. Witchel H. (2011) Drug-induced hERG block and long QT syndrome. Cardiovascul Ther 29: 251–259.
70. Witchel H. Pabbathi V. Hofmann G. Paul A. Hancox J. (2002) Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on hERG and ventricular L-type calcium currents. FEBS Lett 512: 59–66.
71. Yap Y. Camm A. (2003) Drug induced QT prolongation and torsades de pointes. Heart 89: 1363–1372.
72. Zahradnik I. Minarovic I. Zahradnikova A. (2008) Inhibition of the cardiac L-type calcium channel current by antidepressant drugs. J Pharmacol Exp Ther 324: 977–984.
73. Zeltser D. Justo D. Halkin A. Prokhorov V. Heller K. Viskin S. (2003) Torsade de pointes due to noncardiac drugs. Most patients have easily identifiable risk factors. Medicine 82: 282–290.